Holen Sie sich die Stockscreener-App
1.665
3.20%
-0.055
Schlusskurs vom Vortag:
$1.72
Offen:
$1.72
24-Stunden-Volumen:
330.86K
Relative Volume:
0.26
Marktkapitalisierung:
$37.76M
Einnahmen:
$151.12M
Nettoeinkommen (Verlust:
$-194.97M
KGV:
-0.1104
EPS:
-15.0871
Netto-Cashflow:
$-59.11M
1W Leistung:
-6.98%
1M Leistung:
-21.46%
6M Leistung:
-80.39%
1J Leistung:
-73.70%
1-Tages-Spanne:
$1.65
$1.75
1-Wochen-Bereich:
$1.65
$1.84
52-Wochen-Spanne:
$1.65
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
1.665 | 39.01M | 151.12M | -194.97M | -59.11M | -15.09 |
VRTX
Vertex Pharmaceuticals Inc
|
521.09 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.68 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.59 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.45 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.16 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-02-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-13 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Why Is KPTI Stock Down 69% After-Hours Today? - Stocktwits
Karyopharm Therapeutics Stock Price Forecast. Should You Buy KPTI? - StockInvest.us
Israel Englander group discloses new Karyopharm stake (NASDAQ: KPTI) - Stock Titan
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates - finance.yahoo.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - investors.karyopharm.com
Karyopharm Seeks FDA Approval for XPOVIO Plus Ruxolitinib in Myelofibrosis - Cure Today
A Second Drug for a Disease That Has Only Ever Had One: Karyopharm Files for Selinexor Plus Ruxolitinib in Myelofibrosis - Onco'Zine
Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis - marketscreener.com
Karyopharm Therapeutics submits sNDA seeking accelerated approval for selinexor plus ruxolitinib in myelofibrosis - TradingView
KPTI Looks 60.5% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - Karyopharm
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Share Price, KPTI Stock News, KPTI Share Price & Updates - Kalkine
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - FinancialContent
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock - Yahoo Finance
Conferencia de resultados del 2T de 2026 de Karyopharm (KPTI): foco en la sNDA de selinexor y la liquidez - TradingKey
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript - AOL.com
KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView
Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st
RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap - Stock Titan
Karyopharm Therapeutics (KPTI): Commodore Capital now reports 0.0% ownership - Stock Titan
KPTI|Karyopharm Therapeutics Inc|Price:2.015|Chg%:+0.025 - TradingKey
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Karyopharm (KPTI) Ergebniskonferenz Q2 2026: Fokus auf Selinexor-sNDA und Liquidität - TradingKey
Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... - Yahoo! Finance Canada
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highl - GuruFocus
It's crunch time for Karyopharm as company faces potential default next month - Fierce Pharma
Karyopharm Therapeutics has cash to last only into next month - The Business Journals
Karyopharm Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com Australia
Karyopharm Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August - Investing.com
Karyopharm Q2 2026 slides: myelofibrosis data shines amid cash crunch - Investing.com
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KPTI: Selinexor sNDA for myelofibrosis advances amid strong data, stable sales, and liquidity focus - TradingView
Earnings call transcript: Karyopharm Q2 2026 loss widens as cash pressure mounts - Investing.com
Karyopharm Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) 2026-08-13 - Seeking Alpha
Form 8K Karyopharm Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026 - marketscreener.com
Is Karyopharm Therapeutics Inc (KPTI) Undervalued at 64.1%? Q2 E - GuruFocus
Karyopharm Therapeutics Inc. Q2 2026: Revenue $33.4M, Net loss $67M, EPS $(2.32) — 10-Q Summary - TradingView
Karyopharm Therapeutics: Q2 Earnings Snapshot - Barchart.com
Karyopharm Reports $33.4 Million Q2 Revenue and $67 Million Net Loss - Quiver Quantitative
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission - Karyopharm
BRIEF-Karyopharm Therapeutics Q2 Net Income USD -67.023 Million - TradingView
Adage Capital reports 1.54M Karyopharm (KPTI) shares, a 6.78% stake - Stock Titan
Karyopharm Therapeutics Inc Stock Short Interest Rises to 33.51% - Quiver Quantitative
Goldman Sachs Group (KPTI) discloses 6.3% beneficial stake in Karyopharm - Stock Titan
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Karyopharm Therapeutics Inc-Aktie (KPTI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Poulton Stuart | EVP, Chief Development Officer |
Jul 28 '26 |
Sale |
7.10 |
189 |
1,342 |
94,632 |
| Poulton Stuart | EVP, Chief Development Officer |
May 14 '26 |
Sale |
9.50 |
403 |
3,828 |
94,821 |
| Rangwala Reshma | EVP & Chief Medical Officer |
May 14 '26 |
Sale |
9.50 |
408 |
3,876 |
56,829 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
May 14 '26 |
Sale |
9.50 |
324 |
3,078 |
107,940 |
| Abate Kristin | Chief Accounting Officer |
May 14 '26 |
Sale |
9.50 |
53 |
504 |
23,801 |
| Paulson Richard A. | President and CEO |
May 14 '26 |
Sale |
9.50 |
2,203 |
20,928 |
269,747 |
| Mano Michael | EVP, CLO&Secretary |
May 14 '26 |
Sale |
9.50 |
266 |
2,527 |
94,398 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 21 '26 |
Sale |
8.94 |
449 |
4,014 |
56,290 |
| Mano Michael | EVP, CLO&Secretary |
Mar 02 '26 |
Sale |
9.41 |
3,526 |
33,178 |
93,964 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 02 '26 |
Sale |
9.41 |
5,066 |
47,669 |
56,739 |
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):